Inventor · disambiguated record
Christoph Hock
Also filed as: HOCK CHRISTOPH · HOCK CHRISTOPHER
21 granted patents·21 pending applications·255 citations·filing 1993–2024
96Inventor score
Files withBIOGEN INT NEUROSCIENCE GMBH11UNIV ZUERICH7NEURIMMUNE HOLDING AG4NITSCH ROGER3UNIV OF ZUERICH3
Top patents by PatentIndex Score
42 records- 0195US9828420B2Method of providing disease-specific binding molecules and targetsUNIV ZUERICH·Filed 2016·Granted Nov 28, 2017·14 cites·22 claims
- 0294US8940272B2Human anti-tau antibodiesNITSCH ROGER·Filed 2011·Granted Jan 27, 2015·31 cites·9 claims
- 0393US8940276B2Human anti-alpha-synuclein antibodiesWEIHOFEN ANDREAS·Filed 2009·Granted Jan 27, 2015·29 cites·26 claims
- 0492US10202445B2Method of providing disease-specific binding molecules and targetsUNIV ZUERICH·Filed 2017·Granted Feb 12, 2019·7 cites·13 claims
- 0591US10131708B2Methods of treating Alzheimer's diseaseUNIV OF ZUERICH·Filed 2017·Granted Nov 20, 2018·12 cites·88 claims
- 0691US8906367B2Method of providing disease-specific binding molecules and targetsNITSCH ROGER·Filed 2008·Granted Dec 9, 2014·29 cites·21 claims
- 0790US9896504B2Human anti-alpha-synuclein antibodiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2016·Granted Feb 20, 2018·8 cites·75 claims
- 0890US9605059B2Human anti-tau antibodiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2014·Granted Mar 28, 2017·12 cites·70 claims
- 0989US9670272B2Method of providing disease-specific binding molecules and targetsUNIV OF ZÜRICH·Filed 2012·Granted Jun 6, 2017·14 cites·10 claims
- 1089US9580493B2Anti-α synuclein binding moleculesWEIHOFEN ANDREAS·Filed 2012·Granted Feb 28, 2017·16 cites·58 claims
- 1186US10259866B2TDP-43 specific binding moleculesBIOGEN INT NEUROSCIENCE GMBH·Filed 2016·Granted Apr 16, 2019·7 cites·88 claims
- 1285US10301381B2Anti-alpha synuclein binding moleculesBIOGEN INT NEUROSCIENCE GMBH·Filed 2018·Granted May 28, 2019·4 cites·16 claims
- 1385US2024254256A1Human Anti-SOD1 AntibodiesNEURIMMUNE HOLDING AG·Filed 2024·Application pending·0 cites
- 1484US9975947B2Anti-alpha synuclein binding moleculesBIOGEN INT NEUROSCIENCE GMBH·Filed 2017·Granted May 22, 2018·4 cites·15 claims
- 1584US9587014B2TDP-43 specific binding moleculesBIOGEN INT NEUROSCIENCE GMBH·Filed 2012·Granted Mar 7, 2017·7 cites·33 claims
- 1682US5368329ADual stage inflatorMORTON INT INC·Filed 1993·Granted Nov 29, 1994·45 cites·8 claims
- 1779US9283271B2Human anti-SOD1 antibodiesMONTRASIO FABIO·Filed 2011·Granted Mar 15, 2016·5 cites·21 claims
- 1877US6573276B2Muscarinic M1 agonist as an inhibitor of beta-amyloid (Aβ40 and Aβ42)-synthesisBOEHRINGER INGELHEIM PHARMA·Filed 2002·Granted Jun 3, 2003·10 cites·13 claims
- 1977US2022267471A1Human Anti-SOD1 AntibodiesNEURIMMUNE HOLDING AG·Filed 2022·Application pending·0 cites
- 2077US2022403011A1Method of providing disease-specific binding molecules and targetsUNIV OF ZUERICH·Filed 2022·Application pending·0 cites
- 2173US2021238265A1Human Anti-Tau AntibodiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2020·Application pending·0 cites
- 2271US11352441B2Human anti-SOD1 antibodiesNEURIMMUNE HOLDING AG·Filed 2019·Granted Jun 7, 2022·0 cites·14 claims
- 2371US10344097B2Human anti-SOD1 antibodiesNEURIMMUNE HOLDING AG·Filed 2016·Granted Jul 9, 2019·1 cites·11 claims
- 2470US2019153082A1Method of providing disease-specific binding molecules and targetsUNIV ZUERICH·Filed 2018·Application pending·0 cites
- 2569US11091540B2TDP-43 specific binding moleculesBIOGEN INT NEUROSCIENCE GMBH·Filed 2019·Granted Aug 17, 2021·0 cites·31 claims
- 2669US10703808B2Human anti-alpha-synuclein antibodiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2018·Granted Jul 7, 2020·0 cites·19 claims
- 2766US2019263896A1Method of providing disease-specific binding molecules and targetsUNIV OF ZUERICH·Filed 2018·Application pending·0 cites
- 2865US2015147343A1Method of providing disease-specific binding molecules and targetsNITSCH ROGER·Filed 2014·Application pending·0 cites
- 2964US2013266585A1Method of Providing Disease-Specific Binding Molecules and TargetsUNIV ZUERICH·Filed 2013·Application pending·0 cites
- 3064US2013266586A1Method of Providing Disease-Specific Binding Molecules and TargetsUNIV ZUERICH·Filed 2013·Application pending·0 cites
- 3164US2013266514A1Method of Providing Disease-Specific Binding Molecules and TargetsUNIV ZUERICH·Filed 2013·Application pending·0 cites
- 3263US2019233506A1Human Anti-Tau AntibodiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2018·Application pending·0 cites
- 3358US2018002409A1Human Anti-Tau AntibodiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2017·Application pending·0 cites
- 3454US2023242624A1HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)NEURIMMUNE AG·Filed 2021·Application pending·0 cites
- 3549US2005130233A1Methods of diagnosing or treating Alzheimer's disease on basis of increased cerebrospinal fluid levels of nerve growth factorEVOTEC BIOSYSTEMS AG·Filed 2004·Application pending·0 cites
- 3649US2008188435A1Methods of dignosing or treating depression on basis of increased cerebrospinal fluid levels of neurotrodhin 3EVOTEC BIOSYSTEMS AG·Filed 2008·Application pending·0 cites
- 3749US2015232542A1Human anti-alpha-synuclein antibodiesWEIHOFEN ANDREAS·Filed 2015·Application pending·0 cites
- 3848US2005130165A1Polymorphism of soati useful for identifying risk of developing alzheimer's diseaseFiled 2003·Application pending·0 cites
- 3945US2005177881A1Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determining single nucleotide polymorphismsFiled 2002·Application pending·0 cites
- 4041US2014044644A1Ankyrin g and modulators thereof for the treatment of neurodegenerative disordersSANTUCCIONE CHADHA ANTONELLA·Filed 2012·Application pending·0 cites
- 4141US2006240485A1Method of monitoring immunotherapyUNIV ZUERICH·Filed 2003·Application pending·0 cites
- 4236US2005048492A1Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determining cyp46 genotypeFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christoph Hock files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →